Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2017

01-11-2017 | Clinical Study

Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis

Authors: Anne Fogli, Marie-Véronique Demattei, Laetitia Corset, Catherine Vaurs-Barrière, Emmanuel Chautard, Julian Biau, Jean-Louis Kémény, Catherine Godfraind, Bruno Pereira, Toufik Khalil, Nathalie Grandin, Philippe Arnaud, Michel Charbonneau, Pierre Verrelle

Published in: Journal of Neuro-Oncology | Issue 2/2017

Login to get access

Abstract

Human malignant gliomas exhibit acquisition of either one of two telomere maintenance mechanisms, resulting from either reactivation of telomerase expression or activation of an alternative lengthening of telomeres (ALT) mechanism. In the present study, we analyzed 63 human malignant gliomas for the presence of ALT-specific extrachromosomal circles of telomeric DNA (C-circles) and measured telomerase expression, telomeric DNA content (Telo/Alu method), and telomeric repeat-containing RNAs (TERRA) levels. We also assessed histomolecular markers routinely used in clinical practice. The presence of C-circles significantly correlated with IDH1/2 mutation, MGMT exon 1 methylation, low Ki-67 immunostaining, increased telomeric DNA content, absence of functional ATRX protein and level of HTERT gene expression. In multivariate analysis, we observed a trend to a correlation between elevated TERRA levels and increased survival. Interestingly, the C-circles assay allowed to detect ALT activation in glioblastomas exhibiting wild-type IDH1/2 and ATRX expression. These results suggest that, after the correlations uncovered here have been confirmed on larger numbers of tumors, telomeric markers might be useful in improving diagnosis. They also point out to the utility of using the specific, sensitive and quantitative C-circle and Telo/Alu assays that can work with as few as 30 ng of tumor DNA.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Bryan TM, Englezou A, Dalla-Pozza L et al (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274CrossRefPubMed Bryan TM, Englezou A, Dalla-Pozza L et al (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274CrossRefPubMed
3.
go back to reference Pickett HA, Reddel RR (2015) Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol 22:875–880CrossRefPubMed Pickett HA, Reddel RR (2015) Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol 22:875–880CrossRefPubMed
5.
go back to reference Henson JD, Hannay JA, SmcCarthy SW et al (2005) A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217–225PubMed Henson JD, Hannay JA, SmcCarthy SW et al (2005) A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217–225PubMed
6.
go back to reference Hakin-Smith V, Jellinek DA, Levy D et al (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. The Lancet 361:836–838CrossRef Hakin-Smith V, Jellinek DA, Levy D et al (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. The Lancet 361:836–838CrossRef
7.
go back to reference McDonald KL, McDonnell J, Muntoni A et al (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69:729–736CrossRefPubMed McDonald KL, McDonnell J, Muntoni A et al (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69:729–736CrossRefPubMed
8.
go back to reference Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 1333:425CrossRef Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 1333:425CrossRef
9.
go back to reference Bérubé NG (2011) ATRX in chromatin assembly and genomearchitecture during development and disease. Biochem Cell Biol 89:435–444CrossRefPubMed Bérubé NG (2011) ATRX in chromatin assembly and genomearchitecture during development and disease. Biochem Cell Biol 89:435–444CrossRefPubMed
10.
go back to reference Henson JD, Cao Y, Huschtscha LI et al (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1186CrossRefPubMed Henson JD, Cao Y, Huschtscha LI et al (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1186CrossRefPubMed
11.
12.
go back to reference Fogli A, Chautard E, Vaurs-Barrière C et al (2016) The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients’ survival. Carcinogenesis 37:169–176CrossRefPubMed Fogli A, Chautard E, Vaurs-Barrière C et al (2016) The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients’ survival. Carcinogenesis 37:169–176CrossRefPubMed
13.
go back to reference Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322CrossRefPubMed Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322CrossRefPubMed
14.
go back to reference Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211CrossRefPubMed Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211CrossRefPubMed
15.
go back to reference Ducray F, Crinière E, Idbaih A et al (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161CrossRefPubMed Ducray F, Crinière E, Idbaih A et al (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161CrossRefPubMed
16.
go back to reference Ducray F, Mokhtari K, Crinière E et al (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808CrossRefPubMed Ducray F, Mokhtari K, Crinière E et al (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808CrossRefPubMed
17.
go back to reference Yeager T, Neumann A, Englezou A et al (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175–4179PubMed Yeager T, Neumann A, Englezou A et al (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175–4179PubMed
18.
go back to reference Kreth S, Heyn J, Grau S et al (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro-Oncol 12:570–579CrossRefPubMedPubMedCentral Kreth S, Heyn J, Grau S et al (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro-Oncol 12:570–579CrossRefPubMedPubMedCentral
19.
go back to reference Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed
20.
go back to reference Sampl S, Pramhas S, Stern C et al (2012) Expression of telomeres in astrocytoma WHO grade 2 t0 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 5:56–65CrossRefPubMedPubMedCentral Sampl S, Pramhas S, Stern C et al (2012) Expression of telomeres in astrocytoma WHO grade 2 t0 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 5:5665CrossRefPubMedPubMedCentral
21.
go back to reference Broccoli D, Godley LA, Donehower LA et al (1996) Telomerase activation in mouse mammary tumours: lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 16:3765–3772CrossRefPubMedPubMedCentral Broccoli D, Godley LA, Donehower LA et al (1996) Telomerase activation in mouse mammary tumours: lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 16:3765–3772CrossRefPubMedPubMedCentral
22.
go back to reference Aubert G, Hills M, Lansdorp PM (2012) Telomere length measurement—caveats and a critical assessment of the available technologies and tools. Mut Res 730:59–67CrossRef Aubert G, Hills M, Lansdorp PM (2012) Telomere length measurement—caveats and a critical assessment of the available technologies and tools. Mut Res 730:59–67CrossRef
23.
go back to reference Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMed
24.
go back to reference Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026CrossRefPubMedPubMedCentral Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026CrossRefPubMedPubMedCentral
25.
go back to reference Azzalin CM, Reichenbach P, Khoriauli L et al (2007) Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318:798–801CrossRefPubMed Azzalin CM, Reichenbach P, Khoriauli L et al (2007) Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318:798–801CrossRefPubMed
26.
go back to reference Azzalin CM, Lingner J (2014) Telomere functions grounding on TERRA firma. Trends Cell Biol 25:29–36CrossRefPubMed Azzalin CM, Lingner J (2014) Telomere functions grounding on TERRA firma. Trends Cell Biol 25:29–36CrossRefPubMed
28.
go back to reference Bower K, Napier CE, Cole SL et al (2012) Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS ONE 7:e50062CrossRefPubMedPubMedCentral Bower K, Napier CE, Cole SL et al (2012) Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS ONE 7:e50062CrossRefPubMedPubMedCentral
29.
go back to reference Royds JA, Al Nadaf S, Wiles AK et al (2011) The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE 6:e26737CrossRefPubMedPubMedCentral Royds JA, Al Nadaf S, Wiles AK et al (2011) The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS ONE 6:e26737CrossRefPubMedPubMedCentral
30.
go back to reference Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRefPubMedPubMedCentral Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRefPubMedPubMedCentral
31.
go back to reference Heaphy CM, Subhawong AP, Hong SM et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615CrossRefPubMedPubMedCentral Heaphy CM, Subhawong AP, Hong SM et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615CrossRefPubMedPubMedCentral
32.
go back to reference Yan W, Zhang W, You G et al (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS ONE 7:e30339CrossRefPubMedPubMedCentral Yan W, Zhang W, You G et al (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS ONE 7:e30339CrossRefPubMedPubMedCentral
33.
go back to reference Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncol 15:469–479CrossRefPubMedPubMedCentral Leu S, von Felten S, Frank S et al (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncol 15:469–479CrossRefPubMedPubMedCentral
34.
go back to reference Ferrandon S, Saultier P, Carras J et al (2013) Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol 47:64–76CrossRefPubMed Ferrandon S, Saultier P, Carras J et al (2013) Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol 47:64–76CrossRefPubMed
35.
go back to reference Flynn RL, Cox KE, Jeitany M et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273–277CrossRefPubMedPubMedCentral Flynn RL, Cox KE, Jeitany M et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273–277CrossRefPubMedPubMedCentral
Metadata
Title
Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis
Authors
Anne Fogli
Marie-Véronique Demattei
Laetitia Corset
Catherine Vaurs-Barrière
Emmanuel Chautard
Julian Biau
Jean-Louis Kémény
Catherine Godfraind
Bruno Pereira
Toufik Khalil
Nathalie Grandin
Philippe Arnaud
Michel Charbonneau
Pierre Verrelle
Publication date
01-11-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2585-7

Other articles of this Issue 2/2017

Journal of Neuro-Oncology 2/2017 Go to the issue